I thought I'd post the response Tomas got on the LLS CML group in case anyone else was interested.
"You only know that because a Flow Cytometry was done on your blood at diagnosis. Most CML patients do not have that done, so it does not come up as an issue. At diagnosis there are numerous aberrations in the blood of a CML patient. Until you have taken the TKI drugs for probably a year or so these early markers cannot be used for prediction. Besides, myeloid progenitors (myeloblasts) expressing CD7+ are not as big an issue as lymphoid progenitors (lymphoblasts) expressing CD7+.
Quote: "In contrast to aberrant myeloid markers, the detection of lymphoid markers by Flow Cytometry at the time of the diagnosis of CP-CML appears to be associated with early progression to lymphoid BP."
The reason is that CML progression to Blast Phase is usually through the lymphoid line, not through the myeloid line. CML is primarily a disease of the myeloid line, but progression is often a lymphoid issue. Therefore, do not worry about these early diagnostic tests when your blood has many issues caused by the CML. The key will be how well you respond to the TKI drug. If you respond to the TKI drugs then all is well. The remainder of these blood aberrations will resolve themselves over time as the TKI drugs do their job."